All In Biotech

Drug Trial Radar · NCT03355209

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

A Two-Part Study of ZX008 in Children and Adults With Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults With LGS, Followed by Part 2: An Open-label Extension to Assess Long-Term Safety of ZX008 in Children and Adults With LGS

Last checked: Nov 20, 2026Latest source record: Jul 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

296

Actual

Start

Nov 27, 2017

Primary completion

May 23, 2024

Study completion May 23, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part, multicenter, double-blind, parallel-group, placebo controlled study to evaluate the effect of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with Lennox-Gastaut syndrome (LGS).

Conditions

  • Lennox Gastaut Syndrome

Interventions

  • ZX008 0.2 or 0.8 mg/kg/dayDrug

    ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.

  • Matching PlaceboDrug

    Placebo will be administered twice a day (BID) in equally divided doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the ZX008 0.8 mg/kg/Day Group Compared to the Placebo GroupTime frame: From Baseline up to 14 weeks [Titration Period (2 weeks) + Maintenance Period (12 weeks)]
  2. Part 2: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Part 2 Baseline until end of the OLE Period (up to 72 months)
  3. Part 2: Percentage of Participants With Serious TEAEsTime frame: From Part 2 Baseline until end of the OLE Period (up to 72 months)

Locations

72 sites in 14 countries. Site status is shown where the registry gives one.

  • Ep0214 107

    Tucson, Arizona

  • Ep0214 144

    Los Angeles, California

  • Ep0214 101

    San Francisco, California

  • Ep0214 103

    Aurora, Colorado

  • Ep0214 149

    Washington D.C., District of Columbia

  • Ep0214 115

    Gulf Breeze, Florida

  • Ep0214 104

    Miami, Florida

  • Ep0214 141

    Orlando, Florida

  • Ep0214 121

    Orlando, Florida

  • Ep0214 117

    Atlanta, Georgia

  • Ep0214 110

    Chicago, Illinois

  • Ep0214 140

    Bethesda, Maryland

  • Ep0214 112

    Boston, Massachusetts

  • Ep0214 136

    Grand Rapids, Michigan

  • Ep0214 147

    Royal Oak, Michigan

  • Ep0214 109

    Rochester, Minnesota

  • Ep0214 132

    Saint Paul, Minnesota

  • Ep0214 105

    Hackensack, New Jersey

  • Ep0214 118

    Livingston, New Jersey

  • Ep0214 150

    Hartsdale, New York

  • Ep0214 142

    New York, New York

  • Ep0214 131

    Cleveland, Ohio

  • Ep0214 143

    Portland, Oregon

  • Ep0214 120

    Philadelphia, Pennsylvania

  • Ep0214 139

    York, Pennsylvania

  • Ep0214 146

    Dallas, Texas

  • Ep0214 126

    Fort Worth, Texas

  • Ep0214 145

    San Antonio, Texas

  • Ep0214 106

    Salt Lake City, Utah

  • Ep0214 125

    Tacoma, Washington

  • Ep0214 301

    Heidelberg, Australia

  • Ep0214 302

    South Brisbane, Australia

  • Ep0214 802

    Brussels, Belgium

  • Ep0214 803

    Brussels, Belgium

  • Ep0214 801

    Edegem, Belgium

  • Ep0214 204

    Toronto, Canada

  • Ep0214 201

    Vancouver, Canada

  • Ep0214 701

    Dianalund, Denmark

  • Ep0214 1004

    Bordeaux, France

  • Ep0214 1006

    Bron, France

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.